Conclusions: In this patient population, late GI morbidity was relatively uncommon, but clinically significant.

Time to development of late GI toxicity was significantly longer in the IMRT group.

CONCLUSIONS: Compared to 3DCRT, IMRT significantly decreased acute and late GI toxicity in patients treated with AD.

Late GI and GU grade 2 toxicity occurred in 1% and 8%.